How can cancer drug prices better match their benefits? Germany offers a cost-saving model

Stat News

10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the government for cancer treatments were more closely aligned with clinical benefits, a new study finds. 

Moreover, the effort led to a 25% drop in prices one year after product launches, prompting the researchers to suggest U.S. policy makers should consider Germany as a cost-saving model.

In reaching their conclusion, the researchers examined data for 57 cancer treatments that were launched in Germany from 2002 to 2017.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Pricing , Value , Germany